AKT1 and urinary bladder cancer: Tong et al. (2019) found differential genes in bladder cancer were mainly enriched in the receptor tyrosine kinase, PI3K-Akt, Ras/MAPK, JAK/STAT, or Wnt signaling pathways and found that inhibitors targeting RTKs, PI3K-AKT and Ras/MAPK had synergistic effects in combination with palbociclib.